SCHEMBL12366165

SCHEMBL12366165

COC(=O)c1ccc2c(c1)C(c1ccc(F)cc1Cl)=CC(C)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK14 Q16539 4/20 0.38
MDM4 O15151 1/20 0.37
MDM2 Q00987 1/20 0.37
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 6/20 0.36
KDM4E B2RXH2 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
HPGD P15428 3/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 2/20 0.35
TNF P01375 1/20 0.35
GAA P10253 1/20 0.35
NR2F2 P24468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12365859 0.89 MAPK14 (0.41) PARP1ALDH1A1MAPK14MAPTKDM4E
SCHEMBL12366191 0.89 SLC6A3 (0.46) ALDH1A1POLBL3MBTL1MAPTKDM4E
SCHEMBL12366263 0.88 PARP1 (0.40) PARP1ALDH1A1MAPK14POLBMAPT
SCHEMBL12366177 0.87 TDP1 (0.39)
SCHEMBL12390216 0.87 PARP1 (0.39) PARP1ALDH1A1MAPK14MAPTKDM4E
SCHEMBL12366139 0.86 PARP1 (0.40) PARP1ALDH1A1MAPK14POLBMAPT
SCHEMBL12366248 0.85 MAPK14 (0.40) PARP1ALDH1A1MAPK14MAPTKDM4E
SCHEMBL12366163 0.85 KMT2A (0.42) ALDH1A1MAPK14POLBMAPTKDM4E
SCHEMBL12366180 0.84 MEN1 (0.40) ALDH1A1MAPK14POLBMAPTKDM4E
SCHEMBL12390212 0.84 MAPT (0.40) PARP1ALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 US disclosed
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 US disclosed
EP-2177505-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E PARP1 2039/4885ALDH1A1 934/4885MAPK14 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.